Change the keyword or sentiment above, then click Apply.
Friday, 11 Sep 20262 updates
↔ AI sentiment: Neutral
69% confidence
Glenmark Launches RYALTRIS in Brazil, Approved in 57 Markets
Glenmark Pharmaceuticals launched RYALTRIS Nasal Spray in Brazil for allergic rhinitis treatment after ANVISA approval.
This marks Glenmark's first globally commercialized branded product, now approved in 57 markets worldwide.
Source: BSE
↗ AI sentiment: Bullish
90% confidence
India Ratings Upgrades Glenmark to IND AA+/Stable, Boosts Outlook
India Ratings upgrades Glenmark Pharma’s long-term bank loans to IND AA+/Stable, affirming short-term ratings at IND A1+.
GPL recognized $560M from ISB 2001 deal in FY26, improving liquidity and profitability with expected cash flows over FY27-FY28.
Source: BSE